The pharmaceutical industry is research intensive. Companies spend millions of dollars and several years developing new drugs and conducting clinical trials. A company can cannot begin to recover this investment through sales until after approval from the Federal Drug Administration (FDA) or similar organizations in other countries.
This company is understandably protective of its intellectual property (IP). It exists in several forms, including documents, spreadsheets, and scientific applications. Losing this information would erode their competitve advantage and could allow others to file for patents preemptively. In both cases, the monetary loss could exceed tens of millions of dollars. When the company decided it needed better visibility into how research and development (R&D) scientists handled sensitive IP, Digital Guardian was there to help!
Check out the slideshow below to learn more about how Digital Guardian secured this company’s IP.
